FDA Device Decisions, August 2025: Pulsed Field Ablation, Bilateral Hypoglossal Nerve Stimulation and Six Original PMAs
One of the six original PMAs FDA approved in August 2025 is the Genio System 2.1 (P240024), an implanted device that stimulates the hypoglossal nerves on both sides to keep the airway open during sleep. The implant has no battery; it is powered wirelessly by an external unit worn on a disposable skin patch.
Its indications cover adults who fail, cannot tolerate or are ineligible for standard treatments, including lifestyle changes, positive airway pressure, oral appliances and pharmacotherapy, and they name tirzepatide as an example of the latter.
Counting records held in RA Craft Database (decisions through August 31, 2026, tallied October 6), FDA cleared 251 510(k)s in August 2025, granted 1 De Novo request and approved 6 original PMAs. These counts have not been reconciled with FDA's own figures. The site holds 510(k), De Novo and PMA records from 2015 onward, and counts for past months can change as the data are updated.
Counts by pathway
August 2025 next to the previous month and the same month a year earlier, with records assigned to a month by FDA decision date.
| Pathway | August 2025 | July 2025 | August 2024 |
|---|---|---|---|
| 510(k) | 251 | 281 | 280 |
| De Novo | 1 | 1 | 4 |
| PMA (original) | 6 | 4 | 5 |
| PMA supplement | 179 | 195 | 163 |
Records held in RA Craft Database, decisions through August 31, 2026.
510(k) clearances were 30 fewer than in July and below August 2024 (280). There were 6 original PMAs.
The busiest product codes
August's 510(k)s spread across 165 product codes. QIH (automated radiological image processing software) led with 8, followed by HRS (plate, fixation, bone) and LLZ (system, image processing, radiological) with 7 each and GEI (electrosurgical, cutting & coagulation & accessories) with 6. A single 510(k) can carry more than one product code, so per-code counts can add up to more than the number of submissions. If your code is on the list, enter it in the Product Code field on Search to see the records sorted by decision date.
De Novo: measuring the brain's response to magnetic stimulation
August's single De Novo grant, Class II, with the classification name and regulation number from its Classification Order:
- Delphi-MD System (DEN250002, QuantalX Neuroscience, Ltd.): Non-invasive evoked response brain stimulator (21 CFR 882.1860)
"21 CFR" refers to Title 21 of the Code of Federal Regulations, where FDA's regulations are codified.
It elicits and records evoked potentials to transcranial magnetic stimulation (TMS) of the primary motor cortex, dorsolateral prefrontal cortex and primary visual cortex, analyzes them and compares them with a normative reference database. The database covers ages 50 to 75, and the indications state that the device is not to be relied on alone to make or confirm a diagnosis. Both the clinical performance and labeling special controls require a description of how the normative database was built.
Original PMAs: six approvals
- Embrace™ Hydrogel Embolic System (P250003, Instylla, Inc.): a hydrogel that forms in the target vessel, for embolization of hypervascular tumors (product code QVG)
- Simplera Sync Sensor, Guardian 4 Sensor (P250012, Medtronic MiniMed, Inc.): continuous glucose sensors for use with the company's automated insulin delivery systems (SFI)
- Genio® System 2.1 (P240024, Nyxoah S.A.): an implanted bilateral hypoglossal nerve stimulator for obstructive sleep apnea (MNQ)
- MMR IHC Panel pharmDx (Dako Omnis) (P250004, Agilent Technologies, Inc.): an immunohistochemistry companion diagnostic for mismatch repair deficiency in colorectal cancer, for nivolumab alone or with ipilimumab (QNH)
- Idylla™ CDx MSI Test (P250005, Biocartis): a companion diagnostic that detects microsatellite instability in colorectal cancer tissue, for the same nivolumab regimens (SFL)
- Globe® Pulsed Field System (P240044, Kardium, Inc.): a mapping and pulsed field ablation catheter system for paroxysmal atrial fibrillation (QZI)
August also brought 179 PMA supplements, which cover changes to already approved PMA devices among other things.
Three devices worth a closer read
1. Genio® System 2.1 (P240024, PMA). According to the Summary of Safety and Effectiveness Data (SSED) that FDA published with the approval, 115 patients were implanted in the single-arm multicenter DREAM study, and both co-primary responder endpoints, based on the apnea-hypopnea index and the oxygen desaturation index, were met. Conditions of approval include five-year follow-up of the study cohort and a new post-approval study of 229 patients followed for five years.
2. Globe® Pulsed Field System (P240044, PMA). A 16 Fr catheter with 122 electrodes that both maps the heart and delivers pulsed field ablation. According to the SSED, 12-month treatment success in the single-arm multicenter PULSAR study was 80.8%, above the 50% performance goal. A post-approval study of about 250 patients followed for 36 months is a condition of approval.
3. Delphi-MD System (DEN250002, De Novo). The device shows the brain's response to TMS against a normative database, so what the output means depends on that database. The special controls therefore require the clinical performance testing to describe how the database was built, including the clinical work-up and statistical methods, and the labeling to describe it as well.
Compare the three devices
Open P240024, P240044 and DEN250002, star (☆) each one, tick "Compare" on all three in My Workspace and press "3 selected for comparison". The comparison table puts their Indications for Use side by side. Before relying on any of this, open "FDA Record" and "Summary PDF" on each record and read the source.
Note: months are assigned by FDA decision date, and counts can change as the data are updated each month.
RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.
← All articles